Table 3 Basic characteristics of the Covid-19 subjects from the ICU cohort and healthy controls from the FoCus cohort.

From: Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease

Basic characteristics of covid-19 subjects and healthy controls

Continuous variables

Covid-19 subjects n = 17

Healthy controls n = 34

Age (years)

57 (40; 73)

50 (± 16)

BMI

–

25 (± 3)

sFRP5 (ng/ml)

1.56 (1.34; 1.65)

3.25 (1.56; 8.91)

Wnt5a (ng/ml)

3.05 (1.50; 3.98)

0.36 (± 0.19)

Granulocytes (cells/l)

7.12 (6.25; 14.90)

–

Leukocytes (× 109/l)

11 (6; 19)

–

Lymphocytes (cells/l)

1.10 (1.04; 1.15)

–

Platelets (cells/l)

220 (101; 278)

–

GOT (U/l)

94 (58; 189)

–

GGT (U/l)

304 (182; 575)

–

IL-6 (pg/ml)

43.05 (19.55; 61.65)

3.1 (2.40; 3.75)

CRP (mg/l)

69 (34.20; 98.10)

1.40 (1.20; 2.50)

Creatinine (µmol/l)

106 (52; 131)

–

D-Dimer (mg/l FEU)

2.9 (1.8; 5.7)

–

Categorical variables

Gender: Male/Female

12 (71%)/5 (29%)

25 (74%)/9 (26%)

Hypertension: Yes/No

9 (53%)/8 (47%)

–

Hyperlipidemia: Yes/No

4 (24%)/13 (76%)

–

Type 2 Diabetes: Yes/No

6 (35%)/11 (65%)

–

  1. Values of normal distribution are shown as mean (standard deviation), values of non-normal distribution are shown as median (25th; 75th percentile); Subjects were matched by age and gender.
Back to article page